In February, Cambodia approved Coronavac for emergency use and started vaccinations in March.
In addition, both seroconversion rates in adults and elderly volunteers were above 90%, indicating favorable immunogenicity of CoronaVac.
Also in August, began trials with 500 people.
Delays in releasing results On 23 December 2020, researchers in Brazil said the vaccine was more than 50% effective, but withheld full results at Sinovac's request, raising questions about transparency as it was the third delay in releasing results from the trials.
Sinovac's CoronaVac clinical studies are listed.
These trials included individuals older than 60.